

India

ADD (no change)

Consensus ratings*: Buy 13	Hold 6 Sell 0
Current price:	Rs1,763
Target price:	Rs1,947
Previous target:	Rs1,681
Up/downside:	10.4%
InCred Research / Consensus:	10.9%
Reuters:	CYIE.NS
Bloomberg:	CYL IN
Market cap:	US\$2,346m
	Rs195,299m
Average daily turnover:	US\$11.1m
	Rs926.5m
Current shares o/s:	110.0m
Free float:	78.0%
*Source: Bloomberg	

Key changes in this note

- Expect 12% revenue CAGR over FY24F-
- Expect 13.9% EBIT CAGR over FY24F-26F.
- Expect 16.1% PAT CAGR over FY24F-26F.



		Source: E	Bloomberg
Price performance	1M	ЗМ	12M
Absolute (%)	9.2	19.9	131.3
Relative (%)	11.2	23.5	108.6

Major shareholders	% held
Amansa Holdings Pvt Ltd	8.7
DSP Value Fund	5.2
Kotak Small Cap Fund	2.6

Analyst(s)



Abhishek SHINDADKAR

T (91) 22 4161 1543

E abhishek.shindadkr@incredcapital.com

Tushar WAVHAL

T (91) 22 4161 1544

E tushar.wavhal@incredcapital.com

Cyient Limited

Continues to execute better

- Cyient expects to achieve the lower end of its FY24F CC growth guidance range of 15%-20%. Reiterates its 150-250bp margin improvement guidance.
- 2QFY24 DET revenue and margin performance largely in line.
- Retain our ADD rating on Cylent with a higher target price of Rs1,947.

Earnings summary

Digital engineering and technology (DET) revenue and EBIT margin performance in 2QFY24 of Cyient was largely in line with estimates. The encouraging growth across aerospace, sustainability & new growth areas was offset by communications, which fell 8.5% gog led by deferred spending and capex postponement. Soft 1HFY24 & tepid 3QFY24F due to macroeconomic challenges implies the lower end of its guidance is realistic while ~260bp yoy improvement in the avg. EBIT margin in 1HFY24 implies margin guidance is in the bag despite headwinds from growth moderation, sustained investments & staggered wage hikes. We adjust estimates, introduce FY26F & shift to FY26F valuation.

Order intake soft gog but healthy yoy

At US\$183.9m, DET order inflow was down 4.8% gog but up 42.2% yoy led by aerospace and sustainability segments. Cyient signed five large deals in the DET in 2QFY24 (vs. six in 1QFY24) with a total contract potential of US\$51.4m. Management commentary suggests that seasonality could drive better order intake in 2HFY24F vs. 1HFY24.

Margin guidance appears to be in the bag

DET EBIT margin performance (up 40bp gog and 400bp yoy at 16.5%) was aided by increase in utilization, better price realization & indirect cost optimization initiatives partly offset by the wage hike impact. Cyient reiterating its FY24F 150-250bp margin improvement guidance appears procedural, given the material beat yoy in 1HFY24 and despite the residual impact of wage hikes. We model an average 16.4% EBIT margin over FY24F-26F.

Retain ADD rating on Cylent with a higher target price of Rs1,947


We retain ADD rating on Cyient with a higher target price of Rs1,947 (Rs1,681 earlier) as we roll forward to FY26F estimates and shift to a SOTP-based target price. We model a 12% US\$ revenue CAGR over FY24F-26F and a ~16% PAT (Rs) CAGR. We value Cyient DET business at 1.2x (1x earlier) target PE/G multiple to arrive at a P/E multiple of 20.7 and applying holding discount to the target price of Cyient DLM. The increase in PE/G multiple is to account for a recovery in the aerospace vertical and better margin execution. Sustained recovery in the aerospace vertical, strong momentum in the automotive vertical (new growth areas) and order book conversion could help achieve our revenue/EBIT margin assumptions. Improving cash conversion and stable dividend payout provides cushion, in our view. Any higher-than anticipated decline in the organic portfolio, delay in the aerospace business recovery and inferior margin execution are key downside risks.


Financial Summary	Mar-22A	Mar-23A	Mar-24F	Mar-25F	Mar-26F
Revenue (Rsm)	45,344	60,159	59,575	67,857	77,810
Operating EBITDA (Rsm)	8,178	10,031	12,273	13,775	17,795
Net Profit (Rsm)	5,223	5,143	6,907	7,956	9,318
Core EPS (Rs)	47.5	50.0	63.0	72.5	85.0
Core EPS Growth	43.6%	5.2%	26.0%	15.2%	17.1%
FD Core P/E (x)	37.12	35.28	27.74	23.75	19.18
DPS (Rs)	24.0	26.0	32.0	38.6	49.7
Dividend Yield	1.36%	1.48%	1.83%	2.19%	2.82%
EV/EBITDA (x)	22.45	19.37	15.72	13.47	11.22
P/FCFE (x)	44.45	23.95	39.51	30.39	24.57
Net Gearing	(33.0%)	1.2%	(1.0%)	(5.0%)	(9.0%)
P/BV (x)	6.22	5.60	5.09	4.61	4.15
ROE	17.2%	16.7%	19.2%	20.4%	22.8%
% Change In Core EPS Estimates			(3.67%)	(2.36%)	
InCred Research/Consensus EPS (x)					

SOURCE: INCRED RESEARCH, COMPANY REPORTS. DET revenue, EBITDA, net profit over FY24F-26F



YE Mar (Rs m)	2QFY24	2QFY23	YoY (%)	1QFY24	QoQ (%)	2QFY24E	Var. (%)
Revenue (US\$ m)	178.1	151	17.9	177	0.6	177.5	0.4
Revenue (Rs m)	17,785	13,962	27.4	16,865	5.5	17,123	3.9
USD-Rs realization	99.9	92.5	8.0	95.2	4.9	96.5	3.5
EBITDA	3,258	2,046	59.2	3,156	3.2	3,236	0.7
EBITDA margin (%)	18.3	14.7	366 bp	18.7	(39 bp)	18.9	(58 bp)
EBIT	2,600	1,416	83.6	2,480	4.8	2,550	2.0
EBIT margin (%)	14.6	10.1	448 bp	14.7	(9 bp)	14.9	(27 bp)
Depreciation	658	630	4.4	676	(2.7)	686	(4.1)
Net other income	-135	-115	17.4	-176	(23.3)	-132	1.9
PBT	2,465	1,301	89.5	2,304	7.0	2,418	2.0
Provision for tax	567	294	92.9	502	12.9	568	(0.2)
% tax rate	23.0	22.6	40 bp	21.8	121 bp	23.5	(50 bp)
Net profit	1,783	791	125.4	1,681	6.1	1,764	1.1
EPS (Rs)	16.1	7.2	125.4	15.2	6.1	16.0	1.1








Operating trends	2QFY22	3QFY22	4QFY22	1QFY23	2QFY23	3QFY23	4QFY23	1QFY24	2QFY24
Revenue (US\$ m)	150.1	157.9	156.7	161.6	174.8	197.0	213.0	205.3	214.9
Growth YoY (%)	11.2	11.7	4.5	12.6	16.5	24.8	35.9	27.0	22.9
Growth QoQ (%)	4.6	5.2	-0.8	3.1	8.2	12.7	8.1	-3.6	4.7
Revenue (Rs. m)	11,116	11,834	11,812	12,501	13,962	16,182	17,514	16,865	17,785
Growth YoY (%)	10.8	13.3	8.1	18.1	25.6	36.7	48.3	34.9	27.4
Growth QoQ (%)	5.0	6.5	-0.2	5.8	11.7	15.9	8.2	-3.7	5.5
EBIT Margin (%)	14.0	13.8	14.3	11.4	10.1	13.2	14.2	14.7	14.6
US\$-INR realized rate	74.1	74.9	75.4	77.4	79.9	82.1	82.2	82.1	82.8
DET business - Employee count	12,035	12,173	12,834	13,581	15,004	14,693	15,172	15,306	15,441
DET - Client (%)	2QFY22	3QFY22	4QFY22	1QFY23	2QFY23	3QFY23	4QFY23	1QFY24	2QFY24
Top 5	33	31.5	30.6	32.1	28.9	25.9	27.8	29.6	29.5
Top 6-10	12.6	12.8	12	11.6	11	9.9	11.4	9.6	9.7
Non-top 10	54.4	55.7	57.4	56.3	60.1	64.2	60.8	60.8	60.8
DET - Client (US\$ m)	2QFY22	3QFY22	4QFY22	1QFY23	2QFY23	3QFY23	4QFY23	1QFY24	2QFY24
Top 5	41.1	40.7	40.0	44.0	43.6	43.5	49.0	52.4	52.5
Top 6-10	15.7	16.5	15.7	15.9	16.6	16.6	20.1	17.0	17.3
Non-top 10	67.8	71.9	75.0	77.2	90.8	107.8	107.1	107.7	108.3
DET - Client YoY (%)	2QFY22	3QFY22	4QFY22	1QFY23	2QFY23	3QFY23	4QFY23	1QFY24	2QFY24
Top 5	3.6	-0.1	-5.3	0.0	6.1	6.9	22.6	19.1	20.4
Top 6-10	29.8	22.5	11.0	8.4	5.8	0.6	28.2	6.9	4.0
Non-top 10	8.8	17.7	18.5	27.4	33.9	49.9	42.9	39.5	19.3
DET - Client QoQ (%)	2QFY22	3QFY22	4QFY22	1QFY23	2QFY23	3QFY23	4QFY23	1QFY24	2QFY24
Top 5	-6.6	-1.1	-1.7	10.1	-0.8	-0.4	12.6	7.0	0.2
Top 6-10	7.0	5.3	-5.2	1.5	4.4	0.1	20.8	-15.4	1.6
Non-top 10	11.8	6.1	4.2	3.0	17.6	18.8	-0.6	0.5	0.6
Incremental revenue (US\$ m)	2QFY22	3QFY22	4QFY22	1QFY23	2QFY23	3QFY23	4QFY23	1QFY24	2QFY24
Top 5	1.8	-3.2	-2.8	3.2	-0.7	7.2	5.5	3.4	0.1
Top 6-10	0.9	4.2	-1.7	-1.0	2.2	0.1	3.5	-3.1	0.3
Non-top 10	7.2	4.1	3.1	2.2	13.6	17.0	-0.7	0.5	0.6
DET - Client metrics	2QFY22	3QFY22	4QFY22	1QFY23	2QFY23	3QFY23	4QFY23	1QFY24	2QFY24
20 m+	3	3	3	4	4	6	7	7	6
10 m+	10	10	11	11	12	12	13	13	13
5 m+	24	27	25	25	30	31	31	31	31
1 m+	76	77	78	81	85	84	84	90	103

Figure 5: SOTP valuation of Cyient	
DET business	
Target P/E	20.7
Target Price (Rs per share)	1,756
DLM business	
Target Market cap (Rsm)	69,784
Cyient stake in DLM	66.7%
Holding co. Discount	55%
DLM value (Rsm)	20,946
Cyient	
DET business market cap (Rs m)	192,571
DLM value (Rsm)	20,946
Target market cap (Rsm)	213,517
Target price (Rs per share)	1,947
	SOURCE: INCRED RESEARCH, COMPANY REPORTS



BY THE NUMBERS





Profit & Loss					
(Rs mn)	Mar-22A	Mar-23A	Mar-24F	Mar-25F	Mar-26F
Total Net Revenues	45,344	60,159	59,575	67,857	77,810
Gross Profit	23,048	30,505	24,013	27,143	31,124
Operating EBITDA	8,178	10,031	12,273	13,775	15,795
Depreciation And Amortisation	(1,922)	(2,566)	(2,435)	(2,714)	(3,035)
Operating EBIT	6,256	7,465	9,837	11,061	12,761
Financial Income/(Expense)	93	(701)	(647)	(661)	(581)
Pretax Income/(Loss) from Assoc.					
Non-Operating Income/(Expense)	635	514			
Profit Before Tax (pre-EI)	6,984	7,278	9,191	10,399	12,180
Exceptional Items		(467)			
Pre-tax Profit	6,984	6,811	9,191	10,399	12,180
Taxation	(1,761)	(1,668)	(2,151)	(2,444)	(2,862)
Exceptional Income - post-tax			-133		
Profit After Tax	5,223	5,143	6,907	7,956	9,318
Minority Interests					
Preferred Dividends					
FX Gain/(Loss) - post tax					
Other Adjustments - post-tax					
Net Profit	5,223	5,143	6,907	7,956	9,318
Recurring Net Profit	5,223	5,496	6,907	7,956	9,318
Fully Diluted Recurring Net Profit	5,223	5,496	6,907	7,956	9,318

Cash Flow					
(Rs mn)	Mar-22A	Mar-23A	Mar-24F	Mar-25F	Mar-26F
EBITDA	8,178	10,031	12,314	14,239	16,913
Cash Flow from Invt. & Assoc.					
Change In Working Capital	(973)	(3,485)	(2,723)	(2,278)	(2,726)
(Incr)/Decr in Total Provisions					
Other Non-Cash (Income)/Expense					
Other Operating Cashflow					
Net Interest (Paid)/Received					
Tax Paid	(1,652)	(1,288)	(2,081)	(2,795)	(3,462)
Cashflow From Operations	5,553	5,258	7,510	9,166	10,725
Capex	(647)	(675)	(2,601)	(2,784)	(2,831)
Disposals Of FAs/subsidiaries	21	23			
Acq. Of Subsidiaries/investments					
Other Investing Cashflow	(3,197)	(9,675)	539	651	752
Cash Flow From Investing	(3,823)	(10,327)	(2,062)	(2,133)	(2,079)
Debt Raised/(repaid)	(545)	3,511			
Proceeds From Issue Of Shares	121	79			
Shares Repurchased					
Dividends Paid	(2,952)	(2,630)	(3,542)	(4,247)	(5,462)
Preferred Dividends					
Other Financing Cashflow	(2,069)	(2,053)	(1,088)	(1,080)	(1,080)
Cash Flow From Financing	(5,445)	(1,093)	(4,630)	(5,327)	(6,542)
Total Cash Generated	(3,715)	(6,162)	819	1,707	2,103
Free Cashflow To Equity	4,361	8,094	4,909	6,383	7,894
Free Cashflow To Firm	1,730	(5,069)	5,448	7,034	8,646

SOURCE: INCRED RESEARCH, COMPANY REPORTS



BY THE NUMBERS...cont'd

Balance Sheet					
(Rs mn)	Mar-22A	Mar-23A	Mar-24F	Mar-25F	Mar-26F
Total Cash And Equivalents	13,532	8,912	9,731	11,438	13,541
Total Debtors	10,319	15,394	17,857	20,509	23,683
Inventories	2,790	4,358	5,241	6,019	6,950
Total Other Current Assets	2,331	3,249	3,249	3,249	3,249
Total Current Assets	28,972	31,913	36,077	41,215	47,424
Fixed Assets	6,921	7,278	7,187	7,123	6,947
Total Investments	3,582	3,463	3,463	3,463	3,463
Intangible Assets	6,662	21,413	21,413	21,413	21,413
Total Other Non-Current Assets	1,736	1,414	1,414	1,414	1,414
Total Non-current Assets	18,901	33,568	33,477	33,413	33,237
Short-term Debt	3,241	4,397	4,397	4,397	4,397
Current Portion of Long-Term Debt					
Total Creditors	5,259	7,142	7,764	8,917	10,297
Other Current Liabilities	4,123	8,692	8,692	8,692	8,692
Total Current Liabilities	12,623	20,231	20,853	22,006	23,386
Total Long-term Debt	23	4,939	4,939	4,939	4,939
Hybrid Debt - Debt Component					
Total Other Non-Current Liabilities	4,093	5,676	5,676	5,676	5,676
Total Non-current Liabilities	4,116	10,615	10,615	10,615	10,615
Total Provisions					
Total Liabilities	16,739	30,846	31,468	32,621	34,001
Shareholders Equity	31,166	34,667	38,119	42,039	46,692
Minority Interests	(32)	(32)	(32)	(32)	(32)
Total Equity	31,134	34,635	38,087	42,007	46,660

Key Ratios					
	Mar-22A	Mar-23A	Mar-24F	Mar-25F	Mar-26F
Revenue Growth	9.7%	32.7%	14.1%	13.9%	14.7%
Operating EBITDA Growth	42.2%	22.7%	22.8%	12.2%	14.7%
Operating EBITDA Margin	18.0%	16.7%	20.6%	20.3%	20.3%
Net Cash Per Share (Rs)	93.44	(3.85)	3.59	19.10	38.22
BVPS (Rs)	283.60	315.12	346.50	382.13	424.43
Gross Interest Cover	15.92	7.47	8.84	10.55	12.88
Effective Tax Rate	25.2%	24.5%	22.9%	25.5%	25.5%
Net Dividend Payout Ratio	37.7%	39.3%	39.0%	38.7%	40.2%
Accounts Receivables Days	61.82	56.44	63.03	63.60	63.44
Inventory Days	35.82	43.99	49.21	50.01	50.08
Accounts Payables Days	80.14	76.32	76.42	74.09	74.19
ROIC (%)	21.7%	26.9%	19.9%	21.3%	24.6%
ROCE (%)	13.9%	14.7%	16.2%	17.2%	19.3%
Return On Average Assets	14.9%	13.8%	14.1%	15.6%	17.8%

SOURCE: INCRED RESEARCH, COMPANY REPORTS, Consolidated Balance sheet and Cash flow



DISCLAIMER

This report (including the views and opinions expressed therein, and the information comprised therein) has been prepared by Incred Research Services Private Ltd.(formerly known as Earnest Innovation Partners Private Limited) (hereinafter referred to as "IRSPL"). IRSPL is registered with SEBI as a Research Analyst vide Registration No. INH000011024. Pursuant to a trademark agreement, IRSPL has adopted "Incred Equities" as its trademark for use in this report.

The term "IRSPL" shall, unless the context otherwise requires, mean IRSPL and its affiliates, subsidiaries and related companies. This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject IRSPL and its affiliates/group companies to registration or licensing requirements within such jurisdictions.

This report is being supplied to you strictly on the basis that it will remain confidential. No part of this report may be (i) copied, photocopied, duplicated, stored or reproduced in any form by any means; or (ii) redistributed or passed on, directly or indirectly, to any other person in whole or in part, for any purpose without the prior written consent of IRSPL.

The information contained in this report is prepared from data believed to be correct and reliable at the time of issue of this report.

IRSPL is not required to issue regular reports on the subject matter of this report at any frequency and it may cease to do so or change the periodicity of reports at any time. IRSPL is not under any obligation to update this report in the event of a material change to the information contained in this report. IRSPL has not any and will not accept any, obligation to (i) check or ensure that the contents of this report remain current, reliable or relevant; (ii) ensure that the content of this report constitutes all the information a prospective investor may require; (iii) ensure the adequacy, accuracy, completeness, reliability or fairness of any views, opinions and information, and accordingly, IRSPL and its affiliates/group companies (and their respective directors, associates, connected persons and/or employees) shall not be liable in any manner whatsoever for any consequences (including but not limited to any direct, indirect or consequential losses, loss of profits and damages) of any reliance thereon or usage thereof.

Unless otherwise specified, this report is based upon reasonable sources. Such sources will, unless otherwise specified, for market data, be market data and prices available from the main stock exchange or market where the relevant security is listed, or, where appropriate, any other market. Information on the accounts and business of company(ies) will generally be based on published statements of the company(ies), information disseminated by regulatory information services, other publicly available information and information resulting from our research. Whilst every effort is made to ensure that statements of facts made in this report are accurate, all estimates, projections, forecasts, expressions of opinion and other subjective judgments contained in this report are based on assumptions considered to be reasonable as of the date of the document in which they are contained and must not be construed as a representation that the matters referred to therein will occur. Past performance is not a reliable indicator of future performance. The value of investments may go down as well as up and those investing may, depending on the investments in question, lose more than the initial investment. No report shall constitute an offer or an invitation by or on behalf of IRSPL and its affiliates/group companies to any person to buy or sell any investments.

The opinions expressed are based on information which are believed to be accurate and complete and obtained through reliable public or other non-confidential sources at the time made. (Information barriers and other arrangements may be established where necessary to prevent conflicts of interests arising. However, the analyst(s) may receive compensation that is based on his/their coverage of company(ies) in the performance of his/their duties or the performance of his/their recommendations. In reviewing this report, an investor should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additional information is, subject to the duties of confidentiality, available on request. The report is not a "prospectus" as defined under Indian Law, including the Companies Act, 2013, and is not, and shall not be, approved by, or filed or registered with, any Indian regulator, including any Registrar of Companies in India, SEBI, any Indian stock exchange, or the Reserve Bank of India. No offer, or invitation to offer, or solicitation of subscription with respect to any such securities listed or proposed to be listed in India is being made, or intended to be made, to the public, or to any member or section of the public in India, through or pursuant to this report.

The research analysts, strategists or economists principally responsible for the preparation of this research report are segregated from the other activities of IRSPL. Information barriers and other arrangements have been established, as required, to prevent any conflicts of interests.

The research analysts, strategists or economists principally responsible for the preparation of this research report are segregated from the other activities of IRSPL. Information barriers and other arrangements have been established, as required, to prevent any conflicts of interests.

IRSPL may have issued other reports (based on technical analysis, event specific, short term views etc.) that are inconsistent with and reach different conclusion from the information presented in this report.

Holding of Analysts/Relatives of Analysts, IRSPL and Associates of IRSPL in the covered securities, as on the date of publishing of this report



	Analyst/ Relative	Entity/ Associates
any financial interests in the company covered in this report (subject company) and nature of such financial interest	NO	NO
actual/beneficial ownership of 1% or more in securities of the subject company at the end of the month immediately preceding the date of publication of the research report or date of the public appearance;	NO	NO
any other material conflict of interest at the time of publication of the research report or at the time of public appearance	NO	NO
received any compensation from the subject company in the past twelve months for investment banking or merchant banking or brokerage services or investment advisory or depository or distribution from the subject company in the last twelve months for products/services other than investment banking or merchant banking or broker- age services or investment advisory or depository or distribution from the subject company in the last twelve months	NO	NO
managed or co-managed public offering of securities for the subject company in the last twelve months	NO	NO
received any compensation or other benefits from the subject company or third party in connection with the research report	NO	NO
served as an officer, director or employee of the subject company	NO	NO
been engaged in market making activity for the subject company	NO	NO

Analyst declaration

- The analyst responsible for the production of this report hereby certifies that the views expressed herein accurately and exclusively reflect his
 or her personal views and opinions about any and all of the issuers or securities analysed in this report and were prepared independently and
 autonomously in an unbiased manner.
- No part of the compensation of the analyst(s) was, is, or will be directly or indirectly related to the inclusion of specific recommendations(s) or view(s) in this report or based any specific investment banking transaction.
- The analyst(s) has(have) not had any serious disciplinary action taken against him/her(them).
- The analyst, strategist, or economist does not have any material conflict of interest at the time of publication of this report.
- The analyst(s) has(have) received compensation based upon various factors, including quality, accuracy and value of research, overall firm performance, client feedback and competitive factors.

IRSPL and/or its affiliates and/or its Directors/employees may own or have positions in securities of the company(ies) covered in this report or any securities related thereto and may from time to time add to or dispose of, or may be materially interested in, any such securities.

IRSPL and/or its affiliates and/or its Directors/employees may do and seek to do business with the company(ies) covered in this research report and may from time to time (a) buy/sell the securities covered in this report, from time to time and/or (b) act as market maker or have assumed an underwriting commitment in securities of such company(ies), and/or (c) may sell them to or buy them from customers on a principal basis and/or (d) may also perform or seek to perform significant investment banking, advisory, underwriting or placement services for or relating to such company(ies) and/or (e) solicit such investment, advisory or other services from any entity mentioned in thisreport and/or (f) act as a lender/borrower to such company and may earn brokerage or other compensation. However, Analysts are forbidden to acquire, on their own account or hold securities (physical or uncertificated, including derivatives) of companies in respect of which they are compiling and producing financial recommendations or in the result of which they play a key part.